BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans ProgressivaGlobeNewsWire • 12/21/20
BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary AngioedemaGlobeNewsWire • 12/16/20
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital ManagementGlobeNewsWire • 12/07/20
BioCryst's Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of ComplementGlobeNewsWire • 12/06/20
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema PatientsGlobeNewsWire • 12/04/20
Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock?Zacks Investment Research • 12/03/20
Allergy Publishes Results from BioCryst's APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE AttacksGlobeNewsWire • 11/30/20
BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 TrialGlobeNewsWire • 11/13/20